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Background: Transcriptional regulation of smooth 
muscle cells is an understudied component of 
intestinal development and physiology.  
Results: Foxf2 deletion from smooth muscle 
causes intestinal malformations and colon 
remodeling. 
Conclusion: Foxf2 regulation of PDGF and 
myocardin/SRF signaling is essential for intestinal 
development and homeostasis. 
Significance: Better understanding transcriptional 
mechanisms regulating postnatal intestine 
development and homeostasis may provide 
therapeutic approaches for congenital and acquired 
gastrointestinal diseases. 
ABSTRACT 
Alterations in Forkhead box F2 gene expression 
have been reported in numerous pathologies 
and Foxf2
-/-
 mice are perinatal lethal with 
multiple malformations; however, molecular 
mechanisms pertaining to Foxf2 signaling are 
severely lacking. In the present study, Foxf2 
requirements in murine smooth muscle cells 
were examined using a conditional knockout 
approach. We generated novel Foxf2-floxed 
mice, which we bred to smMHC-Cre-eGFP mice 
to generate a mouse line with Foxf2 deleted 
specifically from smooth muscle. These mice 
exhibited growth retardation due to reduced 
intestinal length as well as inflammation and 
remodeling of the small intestine. Colons of 
Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 mice had 
expansion of the myenteric nerve plexus and 
increased proliferation of smooth muscle cells 
leading to thickening of the longitudinal smooth 
muscle layer. Foxf2-deficiency in colonic smooth 
muscle was associated with increased expression 
of Foxf1, PDGFa, PDGFb, PDGFRα and 
myocardin. FOXF2 bound to promoter regions 
of these genes indicating direct transcriptional 
regulation. Foxf2 repressed Foxf1 promoter 
activity in co-transfection experiments. We also 
show that knockdown of Foxf2 in colonic 
smooth muscle cells in vitro and in transgenic 
mice increased myocardin/serum response 
factor signaling and increased expression of 
contractile proteins. Foxf2 attenuated 
myocardin/serum response factor signaling in 
smooth muscle cells through direct binding to 
the N-terminal region of myocardin. Our results 
indicate that Foxf2 signaling in smooth muscle 
cells is essential for intestinal development and 
serum response factor signaling.____
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The mammalian gut is derived from the 
endodermal and mesodermal germ layers, which 
give rise to gut epithelium, mesenchyme and 
smooth muscle (1). The enteric nervous system is 
derived from invading cells from the neural crest 
(1). Digestive diseases affect 60 to 70 million 
Americans resulting in 13.5 million 
hospitalizations annually (2). Digestive diseases 
run a gamut from viral infections to irritable bowel 
syndrome and hemorrhoids, and inflict all tissue 
layers (2). To this point, studies of gut 
development and diseases have primarily focused 
on the epithelial layer due to its obvious 
importance in digestion and nutrient absorption. 
However, smooth muscle is also of critical 
importance to gut anatomy and physiology, 
maintaining shape and allowing for motility of 
luminal content. Despite the great breadth of 
knowledge pertaining to vascular smooth muscle 
development and pathology, surprisingly little is 
known about molecular and transcriptional 
mechanisms critical for development of visceral 
smooth muscle lining the gut. 
Development of visceral smooth muscle requires 
controlled cross-talk between epithelial, neuronal 
and mesenchymal cell layers (3-5). The muscularis 
of the gastrointestinal (GI) tract contains two 
distinct smooth muscle layers separated by the 
myenteric plexus; an inner circular layer and an 
outer longitudinal layer (1,6,7). The muscularis 
mucosa is also of mesenchymal origin and 
demonstrates features similar to smooth muscle 
(1). Numerous signaling pathways have been 
identified that play important roles in regulating 
visceral smooth muscle development during 
embryogenesis, including the TGF-β and bone 
morphogenetic protein (BMP) pathways (5,8,9), 
Wnt signaling (9,10), the Hedgehog pathway 
(3,4,9) and a number of growth factor-mediated 
pathways (i.e. PDGF, fibroblast growth factor 
(FGF) and insulin-like growth factor (IGF)) 
(5,7,11,12). However, knowledge pertaining to the 
regulation of postnatal visceral smooth muscle 
development remains scarce.  
The forkhead box (Fox) family of transcription 
factors has been shown to mediate a wide variety 
of cellular activities including embryonic and 
postnatal cell growth, tissue repair after injury, cell 
migration and tumor formation (13). The Foxf 
subgroup contains two members, Foxf1 and Foxf2 
(1,14). Lessons from knockout mice indicate that 
both Foxf members are critical for embryonic 
development as Foxf1
-/-
 mice die in utero (15,16) 
and Foxf2
-/-
 as well as compound heterozygotic 
(Foxf1
+/-
/Foxf2
+/-
) mice die shortly after birth (17). 
Several Fox proteins, including Foxo4, Foxq1 and 
Foxf1, have been shown to be critical for smooth 
muscle cell development via regulation of the 
myocardin/serum response factor (SRF) axis (18-
20). Using in situ hybridization, embryonic Foxf2 
expression has been found in the mesenchyme of 
the oral cavity, limb buds, genitalia, CNS, eyes, 
lung, prostate, ear and placenta as well as the 
lamina propria region and smooth muscle of the 
developing GI tract (21,22). During embryonic 
development, Hedgehog signaling from the 
epithelium induces Foxf2 expression (17); 
however, postnatal Foxf2 expression and signaling 
remain poorly characterized. Studies have shown 
alterations in Foxf2 expression in prostate cancer 
(23) and that Foxf2 decreases the size and 
frequency of colonic polyps in colon adenoma 
(24). Foxf2 has been further shown to mediate 
cardiac metabolism (25) and a W174R amino acid 
substitution has been shown to cause anterior 
segment mesenchymal dysgenesis in the eye 
(Foxf2
W174R
) (26). However, molecular 
mechanisms for Foxf2 signaling in smooth muscle 
cells have not been previously elucidated due to 
lack of mouse models allowing conditional 
inactivation of Foxf2. 
In the present study, we generated a novel Foxf2-
floxed (Foxf2
fl
) mouse line to investigate the 
importance of Foxf2 in smooth muscle cells. By 
breeding these mice with smooth muscle myosin 
heavy chain-Cre mice (smMHC-Cre-eGFP) (27), 
we were able to efficiently delete Foxf2 from 
mature smooth muscle in the gut. Tg(smMHC-Cre-
eGFP
+/-
);Foxf2
-/-
 mice were viable and fertile. 
Juvenile mice showed no difference in size or 
morphology; however, adult Tg(smMHC-Cre-
eGFP
+/-
);Foxf2
-/-
 mice were significantly smaller 
in stature and had a significant decrease in the 
length of the GI tract (both large and small 
intestine). Adult mice had focal inflammatory 
regions in the small intestine and a significant 
increase in thickness of the smooth muscle and 
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enteric neuron layers in the colon. We used colon 
smooth muscle from Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 mice and cultured Foxf2
-/-
 smooth muscle 
cells to demonstrate that Foxf2 regulates the PDGF 
pathway and physically interacts with myocardin 
to inhibit SRF signaling in visceral smooth muscle 
cells. 
EXPERIMENTAL PROCEDURES 
Generation of Foxf2-floxed mice and deletion of 
Foxf2 from smooth muscle myocytes. A LoxP site 
was inserted into the Foxf2 promoter via Foxf2-
targeting vector and PGK-gb2 LoxP/FRT-flanked 
Neomycin (neo) cassette was placed into the first 
intron (Figure 1D). Electroporation of mouse ES 
cells (C57Bl/6 x 129/SVEV) with the Foxf2
fl
-
targeting vector, following neo (G418) selection, 
was performed at the inGenious Targeting 
Laboratory (Stony Brook, NY). PCR analysis with 
multiple primer sets identified ES cells with the 
appropriate Foxf2
fl
-targeted locus. Foxf2
fl
 ES cells 
were subsequently used to generate chimeric mice 
by injection into mouse blastocysts. Mice 
containing the Foxf2
fl
-targeted allele were 
determined by PCR amplification with primers 
flanking the LoxP sequence located in the Foxf2 
promoter (P1 and P2) (Table 1) and primers 
located in the 3’ region of the Foxf2fl allele (P3 and 
P4). Chimeric mice were bred with C57Bl/6 mice 
in the animal facility of Cincinnati Children’s 
Research Foundation to produce Foxf2
fl/+
 mice. 
The neo cassette was deleted by breeding Foxf2
fl/+
 
mice with ACT-FLP1 mice (Jackson Lab) (Figure 
1D). The loss of neo in Foxf2
fl/+
 mice was 
confirmed by PCR using P5 and P6 primers (Table 
1) and sequencing of the Foxf2 locus using mouse 
tail DNA. Foxf2
fl/+
 mice were backcrossed to 
generate viable Foxf2
fl/fl
 mice that were bred into 
the C57Bl/6 background for ten generations. 
Deletion of the Foxf2
fl
 alleles from visceral smooth 
muscle was accomplished through breeding with 
smooth muscle myosin heavy chain-Cre-eGFP 
(smMHC-Cre-eGFP) transgenic mice (C57Bl/6) 
(27). Animal studies were approved by the Animal 
Care and Use Committee of Cincinnati Children’s 
Research Foundation. 
Tissue collection. Intestinal tracts were collected 
from Foxf2
fl/fl 
and Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-
/-
 mice and placed in ice cold, calcium-free, sterile 
PBS. Colons and small intestines were separated at 
this time. Luminal contents were manually forced 
out by gentle manipulation with forceps. Tissues 
destined for immunohistochemistry were placed in 
4% paraformaldehyde at this time. Tissues for 
whole organ RNA were placed in RNA-STAT-60. 
To enrich the smooth muscle layer of the colon, 
colons were split along their length and laid flat 
with the smooth muscle side down. A scalpel was 
then used to scrape away the epithelium and other 
layers leaving behind a smooth muscle enriched 
segment that was then placed in RNA-STAT-60 
for RNA isolation or used for enzymatic digestion 
to prepare a single cell suspension as previously 
described (28).  
Immunohistochemistry. To characterize FOXF2 
expression throughout development of the GI tract, 
intestinal tissues were collected from wildtype 
mice at embryonic day 14.5 (E14.5), E17.5, 
postnatal day 1 (P1) as well as Tg(smMHC-Cre-
eGFP
+/-
);Foxf2
-/-
 and Foxf2
fl/fl
 mice at, E16.5, 
E18.5, P12 and in the adult (8-12 weeks). 
Intestines and abdomens were fixed in 4% 
paraformaldehyde overnight and embedded into 
paraffin blocks. Paraffin sections of 5 µm were 
immunostained with antibodies against FOXF2 
(1:1000; Santa Cruz Biotech), CGRP (1:4000; 
Sigma), PDGFRα (1:200; Santa Cruz Biotech), α-
smooth muscle actin (αSMA; 1:10,000; Sigma-
Aldrich), γSMA (1:1000; 7 Hills Biotech), 
PECAM-1 (1:500; Pharminogen), FOXA2 (1:300; 
7 Hills Biotech), FOXF1 (1:1000;(29)), pan-
CYTOKERATIN (1:500; Sigma), Ki-67 (1:10,000; 
Dako) or Cyclin D1 (1:250; AbCam). Antibody-
antigen complexes were detected using 
biotinylated secondary antibody followed by 
avidin-HRP complex and DAB substrate (Vector 
Labs, Burlingame, CA) as previously described 
(30-34). Sections were counterstained with nuclear 
fast red (Vector Labs). Intestinal sections were also 
stained with hematoxylin and eosin (H&E) to 
evaluate morphology, Masson’s Trichrome to 
detect fibrosis or wheat-germ agglutinin (WGA; 
Sigma) to measure myocyte size. Size of myocytes 
was measured from WGA-stained slides as 
previously described (35,36). Slides were 
photographed using a Zeiss Axioplan2 microscope 
and Axiovision Rel 4.8 software. 
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To detect Cre-dependent reporter activity, 
smMHC-Cre-eGFP mice were crossed with the 
Cre-dependent reporter strain, mT/mG 
(B6.129(Cg)-Gt(ROSA)26Sortm4(ACTB-
tdTomato,-EGFP)Luo/J (Jackson Lab). Tissues 
were harvested from adult double heterozygous 
mice, fixed in 4% paraformaldehyde and frozen in 
OCT tissue freezing media (Tissue-Tech). Frozen 
sections were washed in 100mM Tris pH7.6, 
150mM NaCl, stained with Hoechst, mounted in 
Prolong Gold (Invitrogen) and visualized by 
confocal microscopy (Olympus Fluoview 
FV1000). Under these conditions cytoplasmic 
eGFP encoded by the smMHC-Cre-eGFP 
transgene is washed out of the tissue sections. 
Quantitative real-time RT-PCR (qRT-PCR). Whole 
organ RNA was prepared from small intestine and 
P12 colon. Smooth muscle enriched RNA was 
prepared as described (28) from adult colon of 
individual Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 and 
control Foxf2
fl/fl
 mice using RNA-STAT-60 (Tel-
Test “B” Inc. Friendswood, TX). cDNA was 
generated using the Applied Biosystems High 
Capacity cDNA Reverse Transcription kit 
(Applied Biosystems, Foster City, CA). Evaluation 
of expression levels of specific genes was 
performed by qRT-PCR using inventoried Taqman 
probes (Table 2) and the StepOnePlus Real-Time 
PCR system (Applied Biosystems, Foster City, 
CA) as previously described (37-42). 
Chromatin immunoprecipitation (ChIP) assays. 
Stably transfected mouse rhabdomyosarcoma cells 
with a dual His/Flag-tagged Foxf2 construct were 
generated and used for ChIP analysis. The 
pMIEG3 retroviral vector was used for dual-tagged 
protein expression in mammalian cells and has 
been described previously (43). In order to 
generate a double-tagged construct, Foxf2 ORF 
was PCR-amplified using high-fidelity pfx 
Polymerase with N-terminal Flag and C-terminal 
(His)6 affinity epitopes according to 
manufacturer’s protocol (Invitrogen). Nuclear 
extracts from transfected mouse 
rhabdomyosarcoma cells were cross-linked by 
addition of formaldehyde, sonicated and used for 
immunoprecipitation with anti-6x HIS tag rabbit 
polyclonal antibodies (Abcam) as described 
previously (44-48). DNA fragments were 
approximately 500 base pairs as verified by 
agarose gel. Reverse cross-linked ChIP DNA 
samples were subjected to PCR, using 
oligonucleotides specific to promoter regions of 
mouse PDGFa, PDGFb, PDGFRα, Foxf1 and 
myocardin genes (Table 3). Potential FOXF2 
binding sites were identified using the MacVector 
program and the previously published FOXF2 
consensus binding sequence TA(G)TTTA(G)T 
(44). DNA sites with the highest homology to the 
published FOXF2 consensus binding sequence 
were investigated via ChIP. DNA binding was 
normalized to control ChIP DNA samples, which 
were immunoprecipitated using control rabbit IgG.  
Luciferase and mammalian two-hybrid assays. 
Foxf2 was amplified by RT-PCR from mRNA 
isolated from mouse intestine. The encoded protein 
of 446 amino acids is identical to that encoded by 
NM_010225.2. A Foxf1 mammalian expression 
construct was amplified by PCR from an HFH8 
clone obtained from Robert Costa (44). This 
resulted in expression of a FOXF1 protein of 353 
amino acids identical to that encoded by 
NM_010426.1. Fox expression plasmids were 
transfected together with SRF expression plasmid, 
telokin promoter luciferase reporter gene (-256 to 
+147) and TK-renilla luciferase internal control 
into 10T1/2 cells and luciferase assays performed 
as described previously (46). The Foxf1luciferase 
reporter (-5.3 kb Foxf1 + 3’ RE) and Foxf2 
luciferase reporter (6 repeats of Foxf2 binding 
sequence) genes were transfected into U2OS cells 
and luciferase assays performed as previously 
described (46,49). Mammalian two hybrid assays 
utilizing SRF fused to the GAL4 DNA binding 
domain and myocardin fused to the GAL4 
activation domain were performed as described 
previously (50).  
GST-pulldown assays. GST-SRF and GST-
myocardin bacterial expression plasmids were 
described previously (50-53). GST-NT MRTFA 
(encoding amino acids 1-628) and GST-CT 
MRTFA (encoding amino acids 618-929) were 
generated by PCR amplification of MRTFA 
fragments from the MRTFA mammalian 
expression vector (52). All expression constructs 
were confirmed by DNA sequencing. Full length 
and fragments of Foxf2 were PCR amplified and 
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cloned into pET vectors for expression in bacteria. 
GST-pulldown assays were performed as described 
previously (53).  
Statistical analysis. Student’s T-test was used to 
determine statistical significance. P values <0.05 
were considered significant. Values for all 
measurements were expressed as mean ± standard 
error of mean (SEM). 
RESULTS 
Generation of mice with Foxf2 deletion from 
smooth muscle cells. As Foxf2 expression has been 
poorly studied and the emergence of reliable 
commercial antibodies fairly recent, we performed 
immunohistochemistry on embryonic (E14.5 and 
E17.5), newborn, juvenile (P12) and adult (8-12 
weeks) wildtype mice to investigate FOXF2 
expression patterns in the GI tract during 
development. As early as E14.5 and at E17.5, 
FOXF2-positive nuclei were detected in the 
intestinal mesenchyme located adjacent to the 
epithelial layer (Figure 1A). In the newborn, P12 
and adult, FOXF2 was detected in the lamina 
propria and inner circular smooth muscle layer of 
the muscularis externa in both the small intestine 
and colon (Figure 1B). FOXF2 was not detected in 
the outer longitudinal smooth muscle layer (Figure 
1B). FOXF2 was not expressed in vascular smooth 
muscle cells (data not shown). qRT-PCR analysis 
indicated that Foxf2 expression increases along the 
cranial to caudal axis in the adult gut, with little 
expression in the duodenum and highest expression 
in the colon (Figure 1C). 
To assess Foxf2 requirements in smooth muscle 
cells, we created a PGK-Neo-Foxf2 targeting 
construct and used it for electroporation of ES cells 
(Figure 1D and Materials and Methods). A Foxf2-
floxed (Foxf2
fl
) mouse line was generated and 
confirmed by PCR amplification of tail genomic 
DNA (Figure 1F, G). The neo cassette was deleted 
by crossing the mice with ACT-FLP1 transgenic 
mice (Figure 1D). Foxf2
fl/fl
 mice contain LoxP sites 
flanking exon one of the Foxf2 gene, which 
contains the DNA binding domain and one of two 
transcriptional activation domains of the FOXF2 
protein. Foxf2
fl/fl
 mice were bred with smMHC-
Cre-eGFP mice to delete Foxf2 from intestinal 
smooth muscle. Analysis of Cre-dependent 
reporter mice demonstrated that the smMHC-Cre-
eGFP transgene directs robust Cre activity in the 
smooth muscle layers as well as muscularis 
mucosa but not lamina propria of small intestine 
and colon (Figure 1E).  
Growth retardation and diminished intestinal 
length in Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 mice. 
Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 mice were born 
in normal Mendelian ratio and were viable and 
fertile. As early as E16.5, Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
  mice had a noticeable decrease in 
FOXF2-staining in smooth muscle cells of the 
circular smooth muscle layer, without loss of 
FOXF2 from the lamina propria (Figure 2A), a 
finding consistent with GFP reporter studies 
(Figure 1E). Similar results were obtained from 
adult Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 mice. 
Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 mice exhibited 
loss of FOXF2 from the inner circular muscle layer 
(Figure 2A) and decreased Foxf2 mRNA in the 
colon and small intestine (Figure 2B). Although 
intestine structure and size was unchanged in 
juvenile Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 mice at 
P12, 8-12 week old adult Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 mice had a truncated GI tract with shorter 
small and large intestines (Figure 2 D, E). Adult 
Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 mice also had 
lower body weight than control littermates 
(19.8±1.2 g for Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 
mice compared to 26.4±1.4 g for control mice) and 
less fecal production (1.3±0.3 g/day for 
Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 mice compared 
to 2±0.1 g/day for control mice), indicating 
diminished intestinal function. No intestinal 
abnormalities were observed in mice containing 
only the smMHC-Cre-eGFP transgene (39). 
Focal inflammation in Foxf2 deficient small 
intestine. Decreased Foxf2 protein and mRNA 
were found in Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 
small intestines, a finding consistent with efficient 
deletion of Foxf2 by the smMHC-Cre-eGFP 
transgene (Figure 2A, B). Adult Tg(smMHC-Cre-
eGFP
+/-
);Foxf2
-/- 
small intestines were mostly 
normal in morphology but exhibited ulcer-like 
patches with loss of villus structure and 
inflammatory cell infiltrates (Figure 3A, B). 
Morphological appearance of smooth muscle 
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layers was normal (Figure 3A). Interestingly, the 
small intestine of juvenile (P12) and embryonic 
(E17.5) Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 mice 
were morphologically normal (Figure 3C and data 
not shown), indicating that Foxf2 is important for 
maintaining intestinal structure in adults. 
Increased smooth muscle cell proliferation in 
Foxf2 deficient colons. The outer longitudinal 
smooth muscle layer was significantly thicker in 
adult Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 colons 
compared to control littermates (Figure 4A, B and 
2C). Thicker muscle in the colon of Tg(smMHC-
Cre-eGFP
+/-
);Foxf2
-/-
 mice was not due to 
pronounced hypertrophy as there was no detectable 
difference in myocyte size between control and 
Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 mice (Figure 
4C, D). This would suggest that increased muscle 
thickness was due to hyperplasia. Although no 
myocyte proliferation was observed in adult 
colons, neonatal P12 Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 mice exhibited increased Ki-67 and 
cyclin D1 staining in myocytes from the outer 
longitudinal smooth muscle layer (Figure 4E). 
qRT-PCR analysis confirmed increased expression 
of the cell cycle regulators Cdc 25B, cyclin B1 and 
cyclin D1 in P12 Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 
mice compared to age-matched controls (Figure 
4F). Therefore, increased smooth muscle thickness 
in Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 colons likely 
results from increased or prolonged myocyte 
proliferation during postnatal development and not 
from hypertrophy of individual myocytes. 
Expansion of the myenteric plexus in Tg(smMHC-
Cre-eGFP
+/-
);Foxf2
-/-
 colons. Tg(smMHC-Cre-
eGFP
+/-
);Foxf2
-/-
 mice also had an expanded 
myenteric nerve plexus.  Immunohistochemical 
staining using the calcitonin-related gene protein 
(CGRP), which marks serotonergic neurons, 
showed a clearly enlarged network of enteric 
neurons in adult Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 
mice (Figure 4G). Greater CGRP staining of the 
myenteric plexus was also observed at P12, prior 
to thickening of the longitudinal muscle layer 
(Figure 4G inset). Expansion of the myenteric 
plexus in Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 mice 
was confirmed by immunostaining with antibodies 
against the platelet-derived growth factor receptor 
alpha (PDGFRα) (Figure 4G) which is highly 
expressed in neurons (54-56) and weakly 
expressed in smooth muscle cells (57). Consistent 
with increased PDGFRα staining, qRT-PCR 
analysis showed increased expression of PDGFRα, 
as well as its ligands PDGFa and PDGFb, in 
Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 colons (Figure 
5A).  
Altered expression of genes critical for gut 
morphogenesis in Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 colons. To determine molecular 
mechanisms underlying increased proliferation in 
Foxf2-deficient colons, we examined expression of 
genes critical for the Hedgehog pathway, which 
has been shown to be important for proliferation of 
smooth muscle cells and their mesenchymal 
precursors (3,4,9). Indian Hedgehog (IHH) mRNA 
was increased in adult Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 colons, but was not changed at P12 
(Figure 5B, data not shown). In agreement with 
increased Hedgehog signaling there was increased 
mRNA expression of Hedgehog target genes 
Foxf1, Gli1, Gli2 and the Hedgehog receptor 
Patched in smooth muscle-enriched tissue from 
Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 mice (Figure 
5A). Considerably more FOXF1-positive myocytes 
were observed in the colon of Tg(smMHC-Cre-
eGFP
+/-
);Foxf2
-/-
 compared to control mice (Figure 
5C), further indicating increased Hedgehog 
signaling. qRT-PCR analysis showed elevated 
mRNA levels of Wnt5a, BMP4 and myocardin 
(Figure 5A), factors critical for gut development. 
Despite significant alterations in smooth muscle 
regulatory genes in Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 mice, muscle markers αSMA and γSMA 
were unaltered following Foxf2 deletion (Figure 
5C), indicating that Foxf2-deficient smooth muscle 
cells are fully differentiated. No fibrosis was 
detected in Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 mice 
as visualized by Masson’s trichrome stain (Figure 
5C). In addition, there was no observed difference 
in vascularization of the muscle layers of the colon 
as indicated by PECAM-1 immunostaining (Figure 
5D). Furthermore, neither FOXA2 nor 
CYTOKERATIN immunostaining demonstrated 
any difference in the structure of colon epithelium 
(Figure 5D). Altogether, our data indicate that 
Foxf2 deletion from smooth muscle cells alters 
expression of genes critical for intestinal 
morphogenesis. 
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Foxf2 binds to promoter regions of PDGFa, 
PDGFb, PDGFRα, myocardin and Foxf1 genes. 
Since expression of genes critical for the PDGF 
and Hedgehog signaling pathways was altered in 
smooth muscle of Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 colons (Figure 5A), we examined 
whether FOXF2 could directly bind to promoter 
regions of these genes. Potential FOXF2-binding 
sites (TGTTTAT, TATTTAT or TATTTGT (44)) 
were identified in the promoter regions of PDGFa, 
PDGFb, PDGFRα and Foxf1 genes. Subsequently, 
a mouse myosarcoma cell line was created that 
stably expressed a His- and Flag-tagged Foxf2 
construct. Chromatin immunoprecipitation (ChIP) 
with anti-HIS antibodies demonstrated that HIS-
FOXF2 bound to the promoter regions of the 
PDGFa, PDGFb and PDGFRα genes (Figure 6A). 
HIS-FOXF2 protein also bound to promoter 
regions of myocardin, a critical co-activator of 
SRF signaling, and Foxf1 transcription factor, a 
downstream target of Hedgehog signaling (Figure 
6B). In co-transfection experiments, FOXF2 
repressed Foxf1 promoter activity in a 
concentration dependent manner as shown by 
Luciferase assay (Figure 6C). Thus, Foxf1 is a 
direct transcriptional target of Foxf2. 
Foxf2 directly interacts with myocardin and 
influences myocardin/SRF signaling. Gene 
expression studies in Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 mice suggest that Foxf2 may regulate 
multiple signaling pathways during gut 
morphogenesis. Next, we focused our studies on 
the myocardin/SRF signaling pathway. SRF and 
myocardin are known to be essential for smooth 
muscle development and function (18). Having 
shown that FOXF2 was able to bind to the 
myocardin promoter, we investigated the effects of 
the FOXF proteins on myocardin/SRF signaling in 
vitro. Co-transfection experiments with an SRF-
dependent luciferase reporter (telokin promoter) 
showed that both FOXF proteins, FOXF1 and 
FOXF2, can increase SRF dependent stimulation 
of the telokin reporter gene in the absence of 
myocardin, though FOXF2 to a lesser extent 
(Figure 7A). A mammalian two-hybrid assay, 
examining the binding of SRF to MYOCARDIN 
also showed that FOXF1 promotes the interaction 
of SRF with MYOCARDIN whereas FOXF2 does 
not (Figure 7B). Utilizing a glutathione pull-down 
assay we showed that FOXF2 protein has a direct, 
physical interaction with MYOCARDIN protein 
(Figure 7C). FOXF2 was found to bind strongly to 
the N-terminus of MYOCARDIN (Myo NT 1-
585). FOXF2 weakly bound to SRF, the C-
terminus of MYOCARDIN (Myo CT 585-935) and 
the N-terminus of the myocardin family member, 
MRTFA (Figure 7C).  Further analysis of 
myocardin deletion mutants determined that 
FOXF2 binds to a region within the first 350 
amino acids of MYOCARDIN (Figure 7D), which 
contains two RPEL motifs (58). Interestingly, this 
is distinct from FOXF1 which binds to the 
MYOCARDIN SAP domain (18).  
To investigate functional consequences of FOXF2 
binding to MYOCARDIN on expression of SRF 
target genes, adenoviral Cre-mediated deletion of 
Foxf2-floxed alleles was performed in a primary 
culture of colon smooth muscle cells purified from 
Foxf2
fl/fl
 mice. Foxf2 mRNA was nearly 
completely ablated indicating efficient Foxf2 
deletion from primary smooth muscle cells (Figure 
7E). Foxf2 deletion significantly increased Foxf1 
mRNA (Figure 7E), a finding consistent with 
increased Foxf1 expression in Foxf2-deficient 
colons (Figure 5A). Foxf2 knockdown increased 
expression of SRF target genes smooth muscle 22α 
(sm22α), αSMA, γSMA, smMHC and myocardin 
in vitro (Figure 7E). Furthermore, increased 
mRNA levels of SRF target genes were observed 
in colon tissue obtained from adult Tg(smMHC-
Cre-eGFP
+/-
);Foxf2
-/-
 mice (Figure 7F). Thus, 
Foxf2-deficiency in colonic smooth muscle cells 
causes increased expression of genes regulated by 
the SRF signaling pathway. Altogether, our results 
indicate that FOXF2 directly binds to myocardin 
and inhibits myocardin/SRF signaling in smooth 
muscle cells. 
DISCUSSION 
 To circumvent perinatal lethality in Foxf2
-/-
 mice, 
we generated a novel mouse model in which Foxf2 
is selectively deleted from smooth muscle cells 
beginning at mid-gestation and throughout the life 
of the mouse. Loss of Foxf2 from smooth muscle 
decreased the length of the intestinal tract, 
truncating both the small intestine and colon. Foxf2 
deletion resulted in increased thickness of 
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longitudinal smooth muscle and expansion of the 
myenteric nerve plexus. PDGFRα-positive nerves 
have been previously observed in the GI tract (54), 
and staining of control and Tg(smMHC-Cre-
eGFP
+/-
);Foxf2
-/-
 colons showed PDGFRα clearly 
localized to the myenteric plexus with increased 
staining in Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 mice. 
Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 colons also had 
elevated expression of PDGFa and PDGFb. 
Increased PDGF signaling can contribute to 
expansion of the myenteric plexus in Foxf2-
deficient colons as PDGF signaling has been 
previously shown to induce neural mitosis and 
hyperplasia (55,59,60). Interestingly, Foxf2
-/-
 mice 
have been reported to lack ganglia in the colon 
(17), which is in stark contrast to the increased 
myenteric plexus observed in our Tg(smMHC-Cre-
eGFP
+/-
);Foxf2
-/-
 mice. The reason for this 
discrepancy could be due to the contribution of 
Foxf2-regulated signals from the lamina propria, 
which is not targeted by smMHC-Cre-eGFP and 
thus not Foxf2-deficient in our mouse model. 
Foxf2 may regulate expression of genes essential 
for neural crest cell migration, proliferation or 
survival. Alternatively the difference may be due 
to the timing in which Foxf2 is deleted, as 
smMHC-Cre-eGFP is not detected prior to E12.5 
(27), which is after the initiation of neural crest 
infiltration of the colon (61).  
In addition to expression in enteric neurons, 
PDGFRα and PDGF ligands are expressed in colon 
smooth muscle (1,57). PDGF has been shown to be 
a potent mitogenic agent in smooth muscle cells 
(62), and a cell autonomous role for PDGF 
signaling in smooth muscle proliferation has been 
previously demonstrated (63). Although we did not 
observe any smooth muscle cell proliferation in the 
colon of adult Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 
mice, we did observe increased proliferation 
during early postnatal development. Unlike 
vascular smooth muscle, smooth muscle of the GI 
tract continues to proliferate for the first few days 
after birth. By 12 days after birth, proliferation of 
colon smooth muscle cells in control mice appears 
to have ceased. In contrast, in Tg(smMHC-Cre-
eGFP
+/-
);Foxf2
-/-
 mice there was still detectable 
proliferation in the circular muscle layer of the 
colon and marked proliferation in the longitudinal 
muscle layer. The increased expression of PDGF 
ligands and receptor in Foxf2-deficient colons 
could thus be stimulating proliferation of the 
neonatal colonic smooth muscle and/or delaying 
cell cycle exit. It has been previously shown that 
PDGF ligands originate from the circular muscle 
layer and myenteric plexus of the gut and PDGFRα 
is more highly expressed in the longitudinal 
muscle than the circular smooth muscle layer (57). 
This expression pattern could explain why the 
circular muscle layer is less affected by Foxf2 
deletion, because it lacks the receptor to respond to 
PDGF ligands. Increased expression of PDGF 
proteins, however, does not appear to prevent 
colonic smooth muscle cells from ultimately 
exiting the cell cycle and differentiating. Cell cycle 
exit coupled with the direct increase in myocardin 
expression seen following loss of Foxf2 likely 
contributes to increased expression of contractile 
proteins in the adult colon.  
The experiments performed in this study provide 
novel insight into the in vivo signaling of Foxf2 as 
well as regulatory pathways for postnatal visceral 
smooth muscle development, particularly in the 
intestines. It was previously shown that FOXF1 
and FOXF2 bind to the same consensus cis-acting 
regulatory element sequence (64). This together 
with analysis of global knockout and compound 
Foxf1/f2 heterozygous mice suggests that Foxf1 
and Foxf2 may be partially redundant (17). In 
contrast, our studies have clearly shown that Foxf1 
and Foxf2 have quite distinct roles in GI smooth 
muscle cells. We have previously shown that loss 
of Foxf1 from smooth muscle cells results in 
decreased contractile protein expression (18), 
whereas in this manuscript we found that loss of 
Foxf2 increases expression of these genes. Binding 
experiments show that FOXF1 and FOXF2 bind to 
different regions of MYOCARDIN ((18) and this 
study) and the effects of this binding are quite 
distinct. FOXF2 is a weak activator of SRF-
regulated genes as compared to FOXF1 and 
binding of FOXF1 to MYOCARDIN promotes its 
interaction with SRF, whereas the binding of 
FOXF2 to MYOCARDIN does not. Our data 
indicate that Foxf2 may act as a functional decoy 
for Foxf1, having only minimal co-stimulatory 
activity, at least as pertains to myocardin/SRF 
signaling. In addition, FOXF2 inhibits Foxf1 
 9 
 
promoter activity, which can further exacerbate 
diminished myocardin/SRF signaling. 
In addition to regulating the activity of 
MYOCARDIN/SRF complexes through protein-
protein interactions, FOXF2 also directly affects 
the expression of myocardin through binding to a 
forkhead site in the myocardin promoter. ChIP 
analysis showed that FOXF2 can bind to the 
promoter region of myocardin, implicating Foxf2 
in transcriptional regulation of the myocardin gene. 
Our data indicates that Foxf2 influences GI tract 
development via regulation of PDGF, SRF and 
Hedgehog pathways, all of which have been shown 
to be critical for GI tract development and 
physiology. Foxf2 may directly or indirectly 
regulate expression of genes critical for all three 
pathways and through this regulation mediate 
postnatal intestinal development and maintenance.  
In summary, we generated a novel mouse line 
containing Foxf2-floxed alleles and used it to 
create smooth muscle-specific Foxf2 knockout 
mice. Utilizing this model we demonstrated a 
distinct phenotype for smooth muscle Foxf2 
deletion compared to Foxf2
-/-
 mice. We also 
showed that FOXF2 bound to the promoter region 
of the myocardin gene as well as several members 
of the PDGF and Hedgehog signaling pathways. 
FOXF2 directly binds to and inhibits Foxf1 
promoter activity and regulates SRF signaling 
through a protein-protein interaction with 
MYOCARDIN. Via its capacity to regulate PDGF, 
Hedgehog and SRF signaling, Foxf2 is a critical 
regulator of GI tract development and 
maintenance.
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FIGURE LEGENDS 
Figure 1. Deletion of Foxf2 from GI smooth muscle. Foxf2 is expressed in the mouse GI tract from 
embryonic time points through adulthood. (A-B) Immunostaining with anti-FOXF2 antibodies showed 
restriction of FOXF2 to mesenchymal layers of the developing GI tract at E14.5 and E17.5. Postnatally, 
Foxf2 was expressed in lamina propria [L] and circular muscle layer [C] but was absent from the 
longitudinal muscle layer [LM] and epithelium [E]. (C) qRT-PCR analysis of adult whole organ mRNA 
showed that Foxf2 is more highly expressed in the jejunum and ileum than the duodenum of the small 
intestine and more highly expressed in the colon than small intestine. Expression levels were normalized 
to β-actin (n=3). (D)  Schematic shows Foxf2-floxed targeting construct. LoxP sites (solid triangles) were 
inserted to flank the first exon [E1] of the Foxf2 gene. Locations of primers [P] and sizes of PCR products 
are indicated. Primers used are listed in Table 1. Foxf2
fl/fl
 mice were bred with ACT-FLP1 mice to remove 
neo and later with smMHC-Cre-eGFP mice to delete Foxf2 from smooth muscle cells. (E) Visualization 
of immunofluorescence in frozen-fixed cross sections of adult ileum and colon from smMHC-Cre-eGFP 
mice crossed with the Cre-dependent mT/mG reporter strain. Membrane bound eGFP is detected in the 
smooth muscle layers as well as the muscularis mucosa, but not lamina propria. meGFP is expressed 
stronger in the muscularis mucosa of colon compared to ileum. Abbreviations: CM, circular muscle. LM, 
longitudinal muscle. MP, myenteric nerve plexus. MM, muscularis mucosa. SMF, submucosal 
fibroblasts. EP, epithelium. (F-G) PCR analysis of mouse tail DNA shows the presence of neo cassette, 
Cre transgene, as well as wildtype and Foxf2-floxed alleles. Scale bar = 10 μm. 
Figure 2. Decreased Foxf2 and length of intestinal tract in Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 mice. 
(A-B) FOXF2 staining and Foxf2 mRNA were significantly decreased in Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 embryonic intestines at E16.5 as well as adult small intestine and colon smooth muscle. 
Expression levels were analyzed by qRT-PCR and normalized to β-actin (n=4). *p<0.05 versus control. 
(C) Representative images of H&E stained adult small intestine and colon from Foxf2
fl/fl
 and Tg(smMHC-
Cre-eGFP
+/-
);Foxf2
-/-
 mice are shown. (D) Gross view of intestines from adult Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 and control Foxf2
fl/fl
 mice indicated shorter intestinal tract in Foxf2-deficient mice. (E) 
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Measurements of intestinal tract confirmed it was significantly shorter in Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 mice due to decreased length of small and large intestines. (n=4). Scale bar = 10 μm in A, 100 
μm in C. 
Figure 3. Focal inflammation in Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 small intestine. (A) Adult 
Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 small intestines had mostly normal morphology with focal regions of 
inflammatory infiltration leading to disruption of villus structure, though muscle morphology remained 
normal. (B) CYTOKERATIN (CK) staining shows disruption of villus epithelium in Tg(smMHC-Cre-
eGFP
+/-
);Foxf2
-/-
 small intestines. (C) H&E staining of control and Foxf2-deficient small intestines 
showed normal morphology at P12. Scale bar = 10 μm. 
Figure 4. Increased muscle thickness and expanded myenteric plexus in Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 colons. (A) H&E staining indicated increased muscle thickness in adult Tg(smMHC-Cre-
eGFP
+/-
);Foxf2
-/-
 colons. Enteric neurons [EN] are shown with arrows, whereas longitudinal [LM] and 
circular [CM] smooth muscle layers are indicated by brackets. (B) Measurement of muscle thickness was 
performed in 12 random colon sections with n=4 mice per group. The longitudinal muscle layer was 
significantly thicker (*p<0.05 versus control) in Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 colons. (C) Wheat 
germ agglutinin (WGA) staining and (D) measurement of cell size in adult mice eliminated hypertrophy 
as the cause of muscle thickening. (E) Immunostaining with Ki-67 and cyclin D1 showed increased 
myocyte proliferation (arrows) in Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 colons at P12. Longitudinal and 
circular smooth muscle layers are shown with brackets while epithelial layer is indicated as E 
(arrowheads show epithelial proliferation). (F) mRNA levels of Cdc 25B, cyclin B1 and cyclin D1 were 
increased but Foxm1 mRNA was unaltered in P12 Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 colons. Expression 
levels were determined by qRT-PCR and normalized to β-actin mRNA (n=4). (G) CGRP and PDGFRα 
immunostaining showed expansion of myenteric plexus (arrows) in adult Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 colons. Insets show expanded CGRP staining in P12 Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 colons.  
Scale bar = 10 μm. 
Figure 5. Regulation of gene transcription by Foxf2. (A) Increased expression of Foxf1, Wnt, BMP, as 
well as members of the PDGF, Hedgehog and SRF pathways in smooth muscle isolated from adult 
Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 colons as determined by qRT-PCR. (B) Indian Hedgehog expression 
was increased in whole colon RNA from adult Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 mice. Epidermal growth 
factor receptor (EGFR) expression was unaltered. Expression levels were normalized to β-actin (n=4). 
*p<0.05 versus control. (C) FOXF1-positive myocytes were more abundant in Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 smooth muscle than control myocytes as shown by immunostaining of the adult colon. Despite 
prolonged proliferation and altered gene expression, muscle markers αSMA and γSMA were observed in 
Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 colon. Fibrosis was not observed in adult Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 colons as determined by Masson’s Trichrome staining of intestinal paraffin sections. (D) 
Vasculature was unaltered in adult Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 colons as visualized by PECAM-1 
staining. Epithelial staining for FOXA2 and CYTOKERATIN was normal in adult colons. Scale bar = 10 
μm. 
Figure 6. FOXF2 binds to PDGF, myocardin and Foxf1 promoter regions. (A-B) FOXF2 binds to the 
promoter regions of PDGFa, PDGFb, PDGFRα, myocardin and Foxf1 genes as determined by ChIP 
analysis. ChIP was performed using a rhabdomyosarcoma cell line which stably expressed His- and Flag-
tagged FOXF2 protein. Anti-His antibodies or control IgG were used for ChIP. (n=3) Negative control for 
ChIP included a DNA region 1.7 kb 3’ to the Foxf1 regulatory element (Foxf1 3’ Region). Anti-Flag 
antibody was used for ChIP of Foxf1 to verify results obtained with anti-His antibody. (C) Luciferase 
reporter gene assays show that FOXF2 inhibits transcriptional activity of the Foxf1 promoter (-5.3 kb 
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Foxf1 + 3’ RE) in a dose-dependent manner (left panel). Conversely FOXF2 activated a reporter gene 
driven by multiple copies of a FOXF2 binding site (right panel). (n=3) 
Figure 7. FOXF2 regulates myocardin/SRF signaling in smooth muscle cells. (A) FOXF1 and, to a 
lesser extent, FOXF2 stimulate a SRF-dependent telokin reporter in the absence of myocardin. SRF, 
Foxf1 and Foxf2 expression plasmids were co-transfected with the SRF-dependent telokin reporter gene 
into 10TI1/2 cells. (B) Mammalian two-hybrid assay examining the binding between SRF and 
MYOCARDIN in the presence or absence of FOXF1 or FOXF2. In these assays SRF was fused to the 
GAL4 DNA binding domain [BD] and myocardin to the GAL4 activation domain [AD]. Interaction 
between SRF-BD and MYOCARDIN-AD results in activation of a GAL4-dependent reporter gene 
(SRF/Myo+vector compared to SRF/pACT+vector: pACT- empty GAL4 activation domain vector). 
FOXF1 promotes MYOCARDIN binding to SRF while FOXF2 has no effect on MYOCARDIN/SRF 
binding. (C) GST-pull down assays in which bacterial expressed FOXF2 was incubated with SRF, 
MYOCARDIN or MRTFA-GST fusion proteins. Following extensive washing, glutathione bound fusion 
proteins were analyzed by Western blot (upper panel). Input GST-fusion proteins visualized by Ponceau 
staining are shown in the lower panel. FOXF2 protein physically binds to SRF, the N-terminal half of 
MYOCARDIN (Myo NT 1-585) more weakly to the C-terminal half of MYOCARDIN (Myo CT 585-
935) and weakly with the N-terminal half of MRTFA but not the C-terminal half of MRTFA. (D) Upper 
panel, schematic representation of MYOCARDIN structural domains. Middle panel, GST-pulldown 
assays using various fragments of MYOCARDIN fused to GST. The GST-fusion protein bound FOXF2 
is shown in the middle panel and GST-fusion protein inputs in the lower panel. FOXF2 specifically bound 
to the first 220 amino acids of the MYOCARDIN protein, which contains RPEL motifs. Weak binding 
was also observed to amino acids 221-350 of MYOCARDIN. (E) Adenoviral Cre-mediated deletion of 
Foxf2
fl
 alleles from primary colon smooth muscle cells increased mRNA levels of Foxf1 as well as 
expression of myocardin/SRF target genes SM22α, αSMA, γSMA, smMHC and myocardin. mRNA 
expression levels were quantitated by qRT-PCR and normalized to β-actin (n=6). *p<0.05 versus control. 
(F) mRNA levels of myocardin/SRF target genes SM22α, αSMA, γSMA and smMHC were increased in 
adult Tg(smMHC-Cre-eGFP
+/-
);Foxf2
-/-
 mouse colons (n=4).  
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Table1. Foxf2-floxed allele mouse primers 
Primer name Sequence 
P1 TGGAGGAGTGTTCTCGAATGGAG 
P2 CACTGGACGCCCTTGAGCTG 
P3 CCAGAGGCCACTTGTGTAGC 
P4 AAAGCTTGTGTCTAGCGGTTGTCCAC 
P5 AGCATGTCTTCCTACTCGTTGGAG 
P6 GCTCCTGCCGAGAAAGTATCC 
Primer sets in table were used for genotyping from mouse tail DNA. 
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Table 2. Taqman Probes 
Gene name Assay number 
acta2 Mm00725412_s1 
actb Mm00607939_s1 
actg2 Mm00656102_m1 
bmp4 Mm01321704_m1 
ccnb1 Mm00838401_g1 
ccnd1 Mm00432359_m1 
cdc25b Mm00499136_m1 
Foxf1 Mm00487497_m1 
Foxf2 Mm00515793_m1 
Foxm1 Mm00514924_m1 
gli1 Mm01160468_g1 
gli2 Mm01293116_m1 
myh11 Mm00443013_m1 
myocd Mm00455051_m1 
pdgfa Mm01205760_m1 
pdgfb Mm01298578_m1 
pdgfra Mm01211694_m1 
ptch1 Mm00436026_m1 
sox9 Mm00448840_m1 
srf Mm00491032_m1 
tagln Mm00441661_g1 
wnt5a Mm00437347_m1 
Table lists inventoried Taqman probes used for qRT-PCR analysis of gene expression. 
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Table 3. ChIP Primers  
Gene (Promoter 
region) 
Forward primer (5’-3’) Reverse primer (5’-3’) 
Foxf1 + Enhancer 
(248/255) 
CCCCACCCCTAACGGATTATTTG TCCCCTGCTTCTAAAAACTGTCCC 
Foxf13’Region 
(Negative 
Control) 
ACCACCATCTCCATCACCAGCC CCTCCCGTCCAGAATGTCAAGTC 
Myocardin 
(-4532/-4525 & -
4523/-4516) 
CCTGGGACCACACAAACAAC AGGCTCCGTCTCAGCGTG 
PDGFa 
(-6421/-6414) 
CCCATCATCCTCTCCTCTTTGC GGTAGCCTTTAGAAATGTGTGCCAG 
PDGFb 
(-1435/-1428) 
TAGATGAGTTCTGGGACTGGACT AGACATAACCGGAGGAGAAGAAG 
PDGFRα 
(-531/-524) 
TGTGCCTCCCAATGGATGAAATC CCTCTGTGAGACGGAAGCCTGC 
Primer sets in table were used in ChIP analysis of Foxf2 binding to gene promoter regions (listed in 
parenthesis). 
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